Topotecan
From Anvita Health Wiki
Contents |
Introduction
- Tradename: Hycamtin.
Indications
- treatment of metastatic cancer of the ovary after failure of initial therapy
- treatment of recurrent & stage IVB cervical cancer in combination with cisplatin ONLY if patient has NOT previously received cisplatin [2] ( NGC )
- relapsed small-cell lung cancer (oral topotecan, IV not recommmended)
Contraindications
- pregnant or breast-feeding women
- severe bone marrow suppression Lyophilized powder:
- store at room temperature & protect from light
- reconsitute with 4 mL sterile water for injection ( SWI)
- further dilute in 100 mL D5W
- 2.5 mg/mL + 50 mg of mannitol, pH = 3.5 when reconstituted with 2 mL sterile water for injection ( SWI)
- 4 mg base/vial (as HCl)
Monitor
Adverse-effects
- common (> 10%)
- headache, alopecia (reversible), nausea/vomiting, diarrhea, myelosuppression
- less common (1-10%)
- uncommon (< 1%)
- other
- emetic potential is moderately low (10-30%)
- myelosuppression
- may cause permanent sterility
Drug-interactions
- increased toxicity with filgastim ( G-CSF)
- coadministration with other antineoplastic agents is associated with increased morbidity & mortality (i.e. cisplatin)
More General Terms
Internet Database
PubChem: 60700
PubChem: 438007
PubChem: 5515
PubChem: 60699
PubChem: 438006
References
- Kaiser Permanente Northern California Regional Drug Formulary, 1998
- National Guideline Clearinghouse Topotecan for the treatment of recurrent and stage IVB cervical cancer. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [1]
- Topotecan for the treatment of relapsed small-cell lung cancer. National Institute for Health and Clinical Excellence (NICE) ngc-guideline: [2]
